China biotech’s CRISPR therapy suggests US drugmakers will face competition
manbetx3.0 生物科技公司的CRISPR疗法表明，美国药企将面临竞争

Five people with beta thalassemia who had their blood stem cells genetically altered no longer require regular blood transfusions to stay healthy. Their Chinese-made treatment is likely to be cheaper, and perhaps safer and more effective, than its American counterparts.
5名接受了基因改造造血干细胞治疗的β地中海贫血患者已无需定期输血来维持健康。他们所用的manbetx3.0 研发疗法很可能比美国同类疗法更便宜，或许也更安全、更有效。